Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products for cancer treatment. The company's lead drug candidate is neratinib, an oral tyrosine kinase inhibitor approved for the treatment of HER2-positive breast cancer. Puma has also in-licensed the global rights to alisertib, a selective aurora kinase A inhibitor, and is exploring its potential in various cancer types.